By Fineline Cube 
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a clinical study for its undisclosed target trispecific antibody (TriAb) drug, SCTB39G. This marks a significant step forward in the development of innovative therapies for advanced solid tumors.
Drug Profile
SCTB39G is an innovative TriAb designed to target advanced solid tumors. The drug’s undisclosed target and mechanism of action represent a novel approach in the treatment of these challenging conditions.
Clinical Trial Plan
The company plans to evaluate the safety, tolerability, and preliminary efficacy of SCTB39G in patients with advanced solid tumors. The clinical study will provide valuable data to support the drug’s further development and potential approval.-Fineline Info & Tech